# Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer

> **NCT07188246** · PHASE2 · RECRUITING · sponsor: **London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's** · enrollment: 40 (estimated)

## Conditions studied

- Breast Cancer
- Breast Cancer Stage II
- Breast Cancer Stage III
- Breast Cancer Invasive
- Breast Cancer Triple Negative

## Interventions

- **RADIATION:** Radiation
- **DRUG:** Pembrolizumab (KEYTRUDA®)

## Key facts

- **NCT ID:** NCT07188246
- **Lead sponsor:** London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-19
- **Primary completion:** 2027-07
- **Final completion:** 2029-02
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07188246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07188246, "Neoadjuvant, SBRT With Intratumoural Pembrolizumab Followed by Neoadjuvant Chemotherapy in Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07188246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*